Molecular structure of Istradefylline, CAS Number: 155270-99-8
Istradefylline (CAS 155270-99-8)
See product citations (1)
Alternate Names:
(E)-8-[2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-Purine-2,6-dione; KW-6002
CAS Number:
155270-99-8
Purity:
≥98%
Molecular Weight:
384.43
Molecular Formula:
C20H24N4O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Istradefylline, known for its role as an adenosine A2A receptor antagonist, has found diverse applications in scientific research. By binding to the receptor, it effectively blocks the binding of adenosine, an endogenous ligand of the receptor. This action inhibits receptor activation and subsequently hinders downstream signaling pathways.
Istradefylline (CAS 155270-99-8) References
- Istradefylline: first global approval. | Dungo, R. and Deeks, ED. 2013. Drugs. 73: 875-82. PMID: 23700273
- The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease. | Yabe, I., et al. 2017. Clin Neuropharmacol. 40: 261-263. PMID: 28976411
- Effect of istradefylline on mood disorders in Parkinson's disease. | Nagayama, H., et al. 2019. J Neurol Sci. 396: 78-83. PMID: 30423541
- Freezing of gait in Parkinson's disease: pathophysiology, risk factors and treatments. | Gao, C., et al. 2020. Transl Neurodegener. 9: 12. PMID: 32322387
- Istradefylline Mitigates Age-Related Hearing Loss in C57BL/6J Mice. | Shin, M., et al. 2021. Int J Mol Sci. 22: PMID: 34360766
- Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. | Hauser, RA., et al. 2021. J Parkinsons Dis. 11: 1663-1675. PMID: 34486986
- Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST). | Shimo, Y., et al. 2021. Parkinsonism Relat Disord. 91: 115-120. PMID: 34583302
- Istradefylline: A novel agent in the treatment of 'off' episodes associated with levodopa/carbidopa use in Parkinson disease. | Cummins, L. and Cates, ME. 2022. Ment Health Clin. 12: 32-36. PMID: 35116210
- Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis. | Wang, XL., et al. 2022. Neurosci Lett. 774: 136515. PMID: 35149201
- Separation and identification of an impurity from the istradefylline intermediate. | Xu, H., et al. 2020. RSC Adv. 10: 14493-14499. PMID: 35497116
- Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4+ T-cell hypersecretion of IL-17A and IL-8 in humans. | Tokano, M., et al. 2022. Immunol Med. 45: 244-250. PMID: 35790489
- Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects. | Dewaeles, E., et al. 2022. J Clin Invest. 132: PMID: 36377661
- Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson's disease: Final report of a post-marketing surveillance study in Japan. | Takahashi, M., et al. 2022. J Neurol Sci. 443: 120479. PMID: 36395674
- Istradefylline modulates purinergic enzymes and reduces malignancy-associated factors in B16F10 melanoma cells. | da Silva, JLG., et al. 2022. Purinergic Signal.. PMID: 36522571
- The role of istradefylline in the Parkinson's disease armamentarium. | Müller, T. 2023. Expert Opin Pharmacother.. PMID: 37029952
Inhibitor of:
Adenosine A1-R, Adenosine A2A-R, Adenosine A3-R, DDC, and PED7A.Activator of:
5′-nucleotidase, and GPR52.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Istradefylline, 1 g | sc-488406 | 1 g | $317.00 |